中药联合恩替卡韦治疗乙肝后肝硬化患者血清中ALT、AST以及AST/ALT变化  

Changes of ALT,AST and AST/ALT in Serum for Patients with Cirrhosis after Traditional Chinese Medicine Combined with Entecavir in the Treatment of Hepatitis

作　　者：左琳琳[1] 

机构地区：[1]保定市传染病医院,河北保定071000

出　　处：《辽宁中医药大学学报》2016年第9期193-195,共3页Journal of Liaoning University of Traditional Chinese Medicine

摘　　要：目的:探讨中药联合恩替卡韦治疗乙肝后肝硬化患者血清ALT、AST以及AST/ALT的变化。方法:2013年1月—2014年1月,我院收治乙肝肝硬化患者80例,随机分为观察组和对照组。其中观察组采用中药方剂联合恩替卡韦治疗,对照组患者采用恩替卡韦治疗。治疗3、6以及12个月后,观察两组患者血清丙氨酸氨基转移酶(ALT)、天冬氨酸转氨酶(AST)以及AST/ALT的变化。结果:治疗3个月后观察组患者ALT和AST分别为(114.35±21.39)U/L和(123.76±29.45)U/L,而对照组患者ALT和AST分别为(169.47±24.46)U/L和(192.36±32.13)U/L,比较差异有统计学意义(P<0.05)。治疗6个月后观察组患者ALT和AST分别为(63.17±17.08)U/L和(83.42±12.95)U/L,而对照组患者ALT和AST分别为(109.57±15.03)U/L和(112.84±16.03)U/L,比较差异有统计学意义(P<0.05)。治疗12月后观察组患者ALT和AST分别为(24.47±6.09)U/L和(33.08±3.59)U/L,而对照组患者ALT和AST分别为(59.31±5.42)U/L和(62.05±4.12)U/L,比较差异有统计学意义(P<0.05)。而ALT/AST的比较,差异无统计学意义(P>0.05)。结论:护肝散结中药方剂联合恩替卡韦治疗乙肝肝硬化患者,可以明显改善患者血清ALT和AST指标,并且比单纯使用恩替卡韦起效快,改善肝功能效果更加明显。在乙肝肝硬化的临床治疗过程中,应当重视我国传统医学,注重中西医结合,可以取得更好的治疗效果。Objective ： To investigate the changes of ALT, AST and AST/ALT in serum for patients with cirrhosis after traditional Chinese medicine combined with entecavir therapy in the treatment of hepatitis. Methods： 80 patients with cirrhosis treated in our hospital from January 2013 to January 2014 were selected and randomly divided into the observation group and the control group. The observation group adopted herbal treatment combined with enteeavir, while the control group were treated with entecavir. After 3,6, and 12 months of the treatment, changes in serum alanine aminotransferase （ ALT ）, aspartate aminotransferase （ AST ） and AST/ALT of the two groups were observed. Results ： After 3 months of the treatment, patients＇ ALT and AST in the observation group were respectively （ 114.35 ± 21.39 ）U/L and （ 123.76 ± 29.45 ）U/L, while in the control group, ALT and AST were respectively （ 169.47± 24.46 ）U/L and （ 192.36 ±＋ 32.13 ）U/L, therefore the differences were statistically significant （ P〈0.05 ）. After 6 months of the treatment patients＇ ALT and AST in the observation group were respectively （ 63.17 ± 17.08 ）U/L and （ 83.42 ±12.95 ）U/L, while in the control group patients＇ ALT and AST were respectively （ 109.57 ± 15.03 ）U/L and （ 112.84 ± 16.03 ）U/L, and the differences were statistically significant （P〈0.05）. After 12 months of the treatment patients＇ ALT and AST in the observation group were respectively （ 24.47 ±6.09 ）U/L and （ 33.08 ±3.59 ）U/L, while in the control group patients＇ ALT and AST were respectively（ 59.31 ± 5.42 ）U/L and（ 62.05 ±4.12 ）U/ L, and the differences were statistically significant （ P〈0.05 ）. However, as for the comparison of ALT/AST, the difference was not statistically significant （ P〉0.05 ）. Conclusion ： Chinese medicine of hugansanjie combined with enteeavir therapy in the treatment of patients＇ liver cirrhosis, can significantly improve the levels of serum ALT and AST index

关 键 词：恩替卡韦 丙氨酸氨基转移酶 天冬氨酸转氨酶 

分 类 号：R657.31[医药卫生—外科学]